3//SEC Filing
Vivo Opportunity, LLC 3
Accession 0001213900-23-039907
CIK 0001484565other
Filed
May 14, 8:00 PM ET
Accepted
May 15, 5:01 PM ET
Size
9.0 KB
Accession
0001213900-23-039907
Insider Transaction Report
Form 3
Vivo Opportunity, LLC
10% Owner
Holdings
- (indirect: By Vivo Opportunity Fund Holdings, L.P.)
Tranche A Warrants (right to buy)
Exercise: $1.75→ Common Stock (3,203,093 underlying) - (indirect: By Vivo Opportunity Fund Holdings, L.P.)
Tranche B Warrants (right to buy)
Exercise: $2.50→ Common Stock (5,215,000 underlying)
Footnotes (3)
- [F1]The Tranche A Warrants are immediately exercisable and expire upon the earlier of (i) November 8, 2026 or (ii) 30 days of announcement of positive top-line data from the randomized withdrawal period of the Issuer's Study C602, an open-label extension study pertaining to Diazoxide Choline Extended-Release tablets (DCCR) for the treatment of Prader-Willi syndrome (PWS). Notwithstanding the foregoing, the exercise of such Warrants is subject to a 19.99% beneficial ownership blocking provision, which will terminate upon approval of the Issuer's stockholders of the issuance of shares underlying such Warrants.
- [F2]Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
- [F3]The Tranche B Warrants are immediately exercisable and expire upon the earlier of (i) November 8, 2026 or (ii) 30 days following receipt of Food and Drug Administration's marketing approval of DCCR for the treatment of PWS. Notwithstanding the foregoing, the exercise of such Warrants is subject to a 19.99% beneficial ownership blocking provision, which will terminate upon approval of the Issuer's stockholders of the issuance of shares underlying such Warrants.
Documents
Issuer
SOLENO THERAPEUTICS INC
CIK 0001484565
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001728970
Filing Metadata
- Form type
- 3
- Filed
- May 14, 8:00 PM ET
- Accepted
- May 15, 5:01 PM ET
- Size
- 9.0 KB